- Conditions
- Autism Spectrum Disorder
- Interventions
- Placebo, RO5285119
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 339 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 45
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Orange, California + 41 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1081–1104
of 10,880
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Crohn's Disease
- Interventions
- Brodalumab
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- Not listed
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Jacksonville, Florida • Hammond, Louisiana + 8 more
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- Osimertinib, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 571 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 18
- States / cities
- Sacramento, California • San Francisco, California • Tampa, Florida + 13 more
- Conditions
- Head and Neck Neoplasms, Fibrosis, Lymphedema, Biomarkers, Polymorphism, Genetic, Depression
- Interventions
- Not listed
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Respiratory Failure, Respiratory Failure With Hypoxia, Endotracheal Intubation
- Interventions
- Manual Ventilation, No Manual Ventilation
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 401 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • New Orleans, Louisiana • Nashville, Tennessee + 1 more
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- Not listed
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 254 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Advanced Colorectal Cancer
- Interventions
- DS-8201a 5.4 mg/kg Q3W, DS-8201a 6.4 mg/kg Q3W
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Louisville, Kentucky • Boston, Massachusetts + 5 more
- Conditions
- HER-2 Gene Amplification, Esophagus Cancer, Gastroesophageal Junction Cancer, Stomach Cancer
- Interventions
- MM-111, Paclitaxel, Trastuzumab
- Drug
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Los Angeles, California • Stanford, California + 16 more
- Conditions
- Body Weight Change, Schizophrenia, Schizoaffective Disorder, Psychotic Disorder
- Interventions
- Aripiprazole
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • Anaheim, California • Cerritos, California + 20 more
- Conditions
- Crohn's Disease
- Interventions
- Certolizumab Pegol (CDP870)
- Biological
- Lead sponsor
- UCB Pharma SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 596 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 40 more
- Conditions
- Obesity, Overweight
- Interventions
- Eloralintide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 43
- States / cities
- Chandler, Arizona • Scottsdale, Arizona • Tucson, Arizona + 37 more
- Conditions
- Breast Cancer, Metastatic Breast Cancer, MBC, HER2 Positive, HER2, Estrogen Receptor Positive, ER, Triple Negative
- Interventions
- Lucitanib
- Drug
- Lead sponsor
- Clovis Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 33
- States / cities
- Sedona, Arizona • Bakersfield, California • Fullerton, California + 25 more
- Conditions
- Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Juvenile Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Childhood Acute Lymphoblastic Leukemia, Secondary Myelodysplastic Syndromes
- Interventions
- allogeneic bone marrow transplantation, laboratory biomarker analysis, filgrastim
- Procedure · Other · Biological
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2022
- U.S. locations
- 21
- States / cities
- Arcadia, California • San Francisco, California • Aurora, Colorado + 17 more
- Conditions
- HER2-positive Advanced Solid Tumor
- Interventions
- DB-1303/BNT323, Pertuzumab Injection, Ritonavir, Itraconazole
- Biological · Drug
- Lead sponsor
- DualityBio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 796 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 35
- States / cities
- Cerritos, California • Los Angeles, California • San Diego, California + 29 more
- Conditions
- Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8
- Interventions
- Biopsy, Biospecimen Collection, Capecitabine, Computed Tomography, Fludeoxyglucose F-18, Fluorouracil, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Mitomycin, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Drug · Other + 1 more
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 659
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 438 more
- Conditions
- Schizophrenia, Bipolar Disorder
- Interventions
- Risperidone long acting injectable - New Starts, Risperidone long acting injectable - Continuous Users, Paliperidone Palmitate -New and Continuous Users, Other Antipsychotics - New Starts
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 1,066 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 34
- States / cities
- Bullhead City, Arizona • Colton, California • Imperial, California + 31 more
- Conditions
- Fragile X Syndrome
- Interventions
- arbaclofen, Placebo
- Drug
- Lead sponsor
- Seaside Therapeutics, Inc.
- Industry
- Eligibility
- 5 Years to 11 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Long Beach, California • Sacramento, California + 24 more
- Conditions
- Hearing Loss
- Interventions
- Percutaneous Cochlear Implantation using image guided surgical techniques
- Procedure
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Soft Tissue Sarcoma, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Carcinoma, Breast Carcinoma, Ovarian Carcinoma, Exocrine Pancreatic Carcinoma, Gastric Carcinoma, Melanoma
- Interventions
- SGN-CD47M
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 5
- States / cities
- Cleveland, Ohio • Portland, Oregon • Nashville, Tennessee + 2 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Semaglutide, Placebo (semaglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 72
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Coronado, California + 54 more
- Conditions
- Post Bariatric Hypoglycemia
- Interventions
- Avexitide, Placebo
- Drug · Other
- Lead sponsor
- Amylyx Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 21
- States / cities
- Stanford, California • Aurora, Colorado • Jacksonville, Florida + 16 more
- Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
- Interventions
- Dupilumab SAR231893 (REGN668), Placebo, Mometasone furoate 50 micrograms
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 18
- States / cities
- Long Beach, California • Orange, California • San Diego, California + 15 more
- Conditions
- Obesity, Childhood, Diet, Healthy, Body Weight Changes
- Interventions
- Whole Foods MyPlate Group
- Behavioral
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Post-Bariatric Hypoglycemia
- Interventions
- Pasireotide Diaspartate
- Drug
- Lead sponsor
- RECORDATI GROUP
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 10
- States / cities
- Palo Alto, California • Chicago, Illinois • Metairie, Louisiana + 7 more